What's in SkyePharma AG's pipeline?

SkyePharma AG has 9 drugs in our index: 0 marketed, 0 filed, 8 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with SkyePharma AG's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, AstraZeneca, Chiesi Farmaceutici S.p.A., Teva Branded Pharmaceutical Products R&D, Inc., Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/skyepharma-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

SkyePharma AG — Portfolio Competitive Intelligence Brief

SkyePharma AG pipeline: 0 marketed, 0 filed, 8 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 8 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fluticasone propionate 100	Fluticasone propionate 100	phase 3	Inhaled corticosteroid	Glucocorticoid receptor	Respiratory / Pulmonology
Formoterol fumarate 10	Formoterol fumarate 10	phase 3	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor	Respiratory
Flovent Fluticasone HFA	Flovent Fluticasone HFA	phase 3	Inhaled corticosteroid	Glucocorticoid receptor	Respiratory / Pulmonology
Fluticasone propionate/formoterol fumarate	Fluticasone propionate/formoterol fumarate	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
SKP-Fluticasone	SKP-Fluticasone	phase 3	Inhaled corticosteroid	Glucocorticoid receptor	Respiratory / Pulmonology
SKP FlutiForm HFA pMDI	SKP FlutiForm HFA pMDI	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor	Respiratory/Pulmonology
Fluticasone propionate 250	Fluticasone propionate 250	phase 3	Inhaled corticosteroid (ICS)	Glucocorticoid receptor	Respiratory / Pulmonology
FlutiForm 250/10	FlutiForm 250/10	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology

Therapeutic area mix

Respiratory / Pulmonology · 4
Respiratory/Pulmonology · 3
Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 6 shared drug classes
AstraZeneca · 5 shared drug classes
Chiesi Farmaceutici S.p.A. · 5 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 4 shared drug classes
Sanofi · 3 shared drug classes
Organon and Co · 3 shared drug classes
Research in Real-Life Ltd · 3 shared drug classes
Allergy and Asthma Center of El Paso · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for SkyePharma AG:

Cite this brief

Drug Landscape (2026). SkyePharma AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/skyepharma-ag. Accessed 2026-05-15.